Literature DB >> 2943891

Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems.

P K Sonsalla, J W Gibb, G R Hanson.   

Abstract

Previous studies have demonstrated that the effects of methamphetamine (METH) on dopaminergic and serotonergic systems are likely related to METH-induced increases in dopamine release. The ability of haloperidol to prevent these effects of METH suggests that dopamine receptor activation is involved in mediating these METH actions. The present studies were undertaken to determine what role the dopamine receptor subtype(s) might have in such METH effects. We found that the D1 antagonist, SCH23390, attenuated or blocked the effects of METH on dopaminergic and serotonergic systems, whereas the D2 antagonist, sulpiride, blocked the effects of METH on only the dopaminergic system. The results of the present studies suggest that METH-induced increases in dopaminergic action on both D1 and D2 receptors are associated with the effects of METH on the dopaminergic system. In contrast, dopamine action on D1, but not on D2, receptors appears to be involved in the effects of METH on the serotonergic systems of the neostriatum and the cerebral cortex.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943891

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

1.  The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice.

Authors:  Sarah E Snider; Sarah A Vunck; Edwin J C G van den Oord; Daniel E Adkins; Joseph L McClay; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2012-01-28       Impact factor: 4.432

2.  Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.

Authors:  Pei-Wen Chu; Gregory C Hadlock; Paula Vieira-Brock; Kristen Stout; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurochem       Date:  2010-08-25       Impact factor: 5.372

3.  Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia.

Authors:  Michelle G Baladi; Amy H Newman; Shannon M Nielsen; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2014-03-28       Impact factor: 4.432

Review 4.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

Review 5.  Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review.

Authors:  Jean Lud Cadet; Subramaniam Jayanthi; Xiaolin Deng
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

6.  Role of neurokinin-1 and dopamine receptors on the striatal methamphetamine-induced proliferation of new cells in mice.

Authors:  Ingrid Tulloch; Nane Ghazaryan; Ina Mexhitaj; Dalila Ordonez; Jesus A Angulo
Journal:  Brain Res       Date:  2011-05-15       Impact factor: 3.252

Review 7.  Mechanisms of methamphetamine-induced dopaminergic neurotoxicity.

Authors:  Evan L Riddle; Annette E Fleckenstein; Glen R Hanson
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

8.  Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors.

Authors:  Wenjing Xu; Judy P Q Zhu; Jesus A Angulo
Journal:  Synapse       Date:  2005-11       Impact factor: 2.562

9.  Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice.

Authors:  J P Q Zhu; W Xu; J A Angulo
Journal:  Neuroscience       Date:  2006-05-02       Impact factor: 3.590

10.  Competitive and noncompetitive N-methyl-D-aspartate antagonists protect dopaminergic and serotonergic neurotoxicity produced by methamphetamine in various brain regions.

Authors:  T Ohmori; T Koyama; A Muraki; I Yamashita
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.